ORIC-533
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment[1].
Product Specifications
CAS Number
[2641306-62-7]
UNSPSC
12352005
Target
CD73
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/oric-533.html
Solubility
10 mM in DMSO
Smiles
O[C@H]1[C@@H](O)[C@H](N2C3=NC(Cl)=NC(NC4CCCC4)=C3C=N2)O[C@@H]1CO[C@](P(O)(O)=O)(CO)COCC5=NN=NN5
Molecular Formula
C20H29ClN9O9P
Molecular Weight
605.93
References & Citations
[1]Junttila M R, et al., ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma[J]. Cancer Research, 2022, 82 (12_Supplement) : 2074-2074.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
038111-ML490 100 µL
MAP1LC3B, cleaved (APG8b, MAP1ALC3, Microtubule-associated proteins 1A/1B light chain 3B, Autophagy-related protein LC3 B, Autophagy-related ubiquitin-like modifier LC3 B, MAP1 light chain 3-like protein 2, MAP1A/MAP1B light chain 3 B, Microtubule-associated protein 1 light chain 3 beta) (MaxLight 490) discontinued
Ask
View Details